Atyr Pharma Inc (ATYR) Stock Price, Quote & News

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 731 8389

Fax: 858 731 8394

Website: atyrpharma.com

Address:

10240 Sorrento Valley Road, Suite 300, San Diego, United States

Merlintrader May. 15 at 2:06 PM

$ATYR Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates https://www.merlintrader.com/regulatory-paths-updates-may2026/

0 · Reply

OriginalTradeonrumor May. 15 at 1:54 PM

$ATYR getting flushed again…only thing to do is wait on sidelines and see where the green bar appears. 🙂

0 · Reply

OriginalTradeonrumor May. 15 at 1:30 PM

$ATYR may have another promising drug from this platform —- “AYTR0101 selectively induces myofibroblast apoptosis via modulation of focal adhesion kinase (FAK) signaling through a novel binding interaction with latent-transforming growth factor beta binding protein 1 (LTBP-1) and results in a significant reduction of fibrosis in lung and kidney models.”

1 · Reply

Jack_Danielss May. 15 at 1:15 PM

$ATYR yeah decent update circa $70M cash. Phase 2 and Phase 3 trials under way. Good drug discovery platform, a new target identified for fibrosis. Decent company

0 · Reply

trader2sde May. 15 at 12:41 PM

$ATYR very good report, extreme responsibility with cash. pipeline.

0 · Reply

Cheffinance May. 15 at 12:30 PM

$ATYR good cash position, great work about costs reviuw with manteinment of r/s evolutions. Good pipeline confirmed soon, so very great news!!! Target above 1usd quickly.

0 · Reply

Cheffinance May. 15 at 12:22 PM

$ATYR BOOOOO🤑🎆🚀

0 · Reply

CHItraders May. 15 at 12:20 PM

📊 aTyr Pharma $ATYR Q1 Earnings ✅ Earnings Beat Adj. EPS: $(0.11) YoY: ↑ 35.29% (from $(0.17))

0 · Reply

focafoca99 May. 15 at 12:15 PM

$ATYR issued a press release with its quarter ended March 31, 2026 results.

0 · Reply

Spiceman63 May. 15 at 12:08 PM

$ATYR https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-first-quarter-2026-results-and-provides

1 · Reply

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

May 13, 2026, 4:35 PM EDT - 1 day ago

Ethos Announces Early Lock-Up Release

LIFE

May 13, 2026, 4:01 PM EDT - 1 day ago

aTyr Pharma to Participate in Upcoming Investor Conferences

2026-05-11T23:05:03.000Z - 3 days ago

aTyr Pharma provides regulatory update on efzofitimod following Type C meeting

May 11, 2026, 4:30 PM EDT - 3 days ago

aTyr Pharma Transcript: Study update

May 11, 2026, 4:01 PM EDT - 3 days ago

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

2026-05-08T18:51:05.000Z - 6 days ago

aTyr Pharma Inc options imply 14.1% move in share price post-earnings

May 6, 2026, 4:05 PM EDT - 8 days ago

Ethos Reports First Quarter Fiscal Year 2026 Financial Results

LIFE

May 5, 2026, 9:07 AM EDT - 10 days ago

Ethos Launches ChatGPT App To Bring Instant Life Insurance Estimates to 900 Million Users

LIFE

Apr 23, 2026, 9:07 AM EDT - 22 days ago

Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience

LIFE

Apr 2, 2026, 4:05 PM EDT - 6 weeks ago

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

LIFE

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families

LIFE

Mar 11, 2026, 8:00 AM EDT - 2 months ago

aTyr Pharma Transcript: Leerink Global Healthcare Conference 2026

2026-03-05T21:05:56.000Z - 2 months ago

aTyr Pharma reports Q4 EPS (14c), consensus (17c)

Mar 5, 2026, 4:01 PM EST - 2 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Feb 26, 2026, 4:06 PM EST - 2 months ago

Ethos to Participate in The Citizens Technology Conference

LIFE

Feb 25, 2026, 4:05 PM EST - 2 months ago

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

LIFE

Feb 20, 2026, 4:01 PM EST - 2 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 8:00 AM EST - 3 months ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Feb 5, 2026, 4:05 PM EST - 3 months ago

Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026

LIFE

Feb 3, 2026, 2:46 PM EST - 3 months ago

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

FPS LFTO YSS

2026-02-03T13:10:35.000Z - 3 months ago

aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod

Feb 3, 2026, 8:00 AM EST - 3 months ago

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Jan 29, 2026, 12:30 PM EST - 3 months ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Jan 28, 2026, 10:38 PM EST - 3 months ago

Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 9:05 PM EST - 3 months ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Jan 7, 2026, 8:01 AM EST - 4 months ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Dec 18, 2025, 8:01 AM EST - 5 months ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Dec 15, 2025, 2:45 PM EST - 5 months ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 8, 2025, 3:25 AM EST - 5 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 2, 2025, 1:00 PM EST - 5 months ago

aTyr Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-25T15:09:57.000Z - 6 months ago

aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns

Nov 10, 2025, 8:00 AM EST - 6 months ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

2025-11-06T21:26:32.000Z - 6 months ago

aTyr Pharma reports Q3 EPS (26c), consensus (18c)

Nov 6, 2025, 4:01 PM EST - 6 months ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

2025-11-06T20:35:18.000Z - 6 months ago

aTyr Pharma Inc options imply 21.3% move in share price post-earnings

2025-09-30T10:20:48.000Z - 8 months ago

aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

2025-09-29T20:40:08.000Z - 8 months ago

Piper Sandler healthcare analysts hold an analyst/industry conference call

2025-09-15T20:30:25.000Z - 8 months ago

aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital

2025-09-15T18:00:09.000Z - 8 months ago

Wells Fargo downgrades aTyr Pharma on efzofitimod Phase 3 failure

2025-09-15T17:20:16.000Z - 8 months ago

aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo

2025-09-15T17:05:38.000Z - 8 months ago

aTyr Pharma downgraded to Neutral from Buy at Lucid Capital

2025-09-15T16:40:14.000Z - 8 months ago

aTyr Pharma downgraded to Hold from Buy at JonesResearch

2025-09-15T16:10:25.000Z - 8 months ago

aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright

Merlintrader May. 15 at 2:06 PM

$ATYR Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates https://www.merlintrader.com/regulatory-paths-updates-may2026/

0 · Reply

OriginalTradeonrumor May. 15 at 1:54 PM

$ATYR getting flushed again…only thing to do is wait on sidelines and see where the green bar appears. 🙂

0 · Reply

OriginalTradeonrumor May. 15 at 1:30 PM

1 · Reply

Jack_Danielss May. 15 at 1:15 PM

$ATYR yeah decent update circa $70M cash. Phase 2 and Phase 3 trials under way. Good drug discovery platform, a new target identified for fibrosis. Decent company

0 · Reply

trader2sde May. 15 at 12:41 PM

$ATYR very good report, extreme responsibility with cash. pipeline.

0 · Reply

Cheffinance May. 15 at 12:30 PM

$ATYR good cash position, great work about costs reviuw with manteinment of r/s evolutions. Good pipeline confirmed soon, so very great news!!! Target above 1usd quickly.

0 · Reply

Cheffinance May. 15 at 12:22 PM

$ATYR BOOOOO🤑🎆🚀

0 · Reply

CHItraders May. 15 at 12:20 PM

📊 aTyr Pharma $ATYR Q1 Earnings ✅ Earnings Beat Adj. EPS: $(0.11) YoY: ↑ 35.29% (from $(0.17))

0 · Reply

focafoca99 May. 15 at 12:15 PM

$ATYR issued a press release with its quarter ended March 31, 2026 results.

0 · Reply

Spiceman63 May. 15 at 12:08 PM

$ATYR https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-first-quarter-2026-results-and-provides

1 · Reply

Wallace911 May. 15 at 10:28 AM

$ATYR come back 1$ let's go my darling

0 · Reply

Jack_Danielss May. 15 at 9:27 AM

$ATYR

1 · Reply

trader2sde May. 14 at 10:18 PM

$ATYR things happening.

0 · Reply

Chrissss214 May. 14 at 9:08 PM

$ATYR

0 · Reply

Cheffinance May. 14 at 8:58 PM

$ATYR it's going to close the gap around 1usd waiting for the new study. Then...

1 · Reply

topstockalerts May. 14 at 8:04 PM

$ATYR it’s funny how the quiet ones can become the strongest.

1 · Reply

OriginalTradeonrumor May. 14 at 8:02 PM

$ATYR Wow!! WHAT A CLOSE!!!!! Over 1 million volume spike!!!!!! It’s almost guranteed we trade in the .60’s tomorrow Let’s see what happens!!

1 · Reply

trader2sde May. 14 at 8:01 PM

$ATYR could be that management will be WAY more proactive and aggressive against the shorting community. let's see. like enough is enough. up to them. the can fire a few bullets ( assets/projects/developments/partnerships etc_

0 · Reply

trader2sde May. 14 at 7:58 PM

$ATYR bloc

0 · Reply

trader2sde May. 14 at 7:58 PM

$ATYR

0 · Reply

trader2sde May. 14 at 7:49 PM

$ATYR

0 · Reply

trader2sde May. 14 at 7:49 PM

$ATYR

0 · Reply

Market Cap	38.82M
Revenue (ttm)	190,000.00
Net Income (ttm)	-74.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39,010.53%
Debt to Equity Ratio	0.00

Volume	13,895,200
Avg Vol	1,774,262
Day's Range	N/A - N/A
Shares Out	98.05M
Stochastic %K	25%
Beta	0.66
Analysts	Sell
Price Target	$4.50